Satish Waigaonkar Introduces New Pharmacoeconomics Model

Satish Waigaonkar Honoured with Honorary Doctorate for Transformative Pharmacoeconomics Model in Public Healthcare

Mumbai/Nanded:
In a landmark moment for India’s public health ecosystem, Satish Ramchandra Waigaonkar, Director of Waiko Drugs and Pharma LLP, Nanded, has been awarded an Honorary Doctorate for developing a groundbreaking Pharmacoeconomics-Based Procurement Model. This innovative framework is transforming how government hospitals in Maharashtra select, procure, and utilize medicines—resulting in better clinical outcomes, higher transparency, and significant cost savings.

At a time when public healthcare systems face challenges of rising costs, inconsistent quality, and medicine-related inefficiencies, Waigaonkar’s model introduces a scientific, data-driven, and patient-centric approach that aligns treatment quality with economic efficiency.

A Scientific Breakthrough in Drug Procurement

Waigaonkar’s model evaluates medicines through stringent parameters before procurement, including:

Bioavailability and clinical efficacy
Treatment duration and recovery outcomes
Real-world patient response data
Quality and compliance of vendors
Cost-effectiveness without compromising clinical value

This ensures that government hospitals procure only high-quality, clinically potent, and outcome-oriented medicines, leading to faster recovery and reduced burden on the healthcare system.

Health economists describe this breakthrough as “a model of national importance”, with potential for countrywide adoption.

Measurable Impact Across Maharashtra

In district hospitals where the model is already operational, the results have been remarkable:

20–30% reduction in treatment duration
25–40% reduction in procurement wastage
Lower hospital bed occupancy rates
Reduction in emergency purchases and stock-outs
Improved transparency in drug selection and vendor assessment

By eliminating low-efficacy and poor-quality medicines, hospitals saw faster patient recovery, better antibiotic stewardship, and optimized use of government budgets.

Healthcare administrators confirm that the model has strengthened decision-making in:

Antibiotic and antimicrobial selection
Injectable vs. oral therapy optimisation
Culture-sensitivity-based drug choices
Vendor compliance and documentation verification
High-bioavailability drug procurement

This scientific method of purchasing medicines is now considered one of Maharashtra’s most impactful healthcare innovations.

A Recognition that Redefines Public Health Standards

Upon receiving the Honorary Doctorate, Dr. Satish Waigaonkar said:

“Pharmacoeconomics is not just about reducing costs. It is about ensuring that every patient receives safe, effective, and scientifically validated treatment. This recognition belongs to the entire health department that believed in this vision.”

Officials from the Maharashtra Health Department echo the sentiment, noting that the model has become a game-changer for:

Hospital administrators
Procurement committees
Pharmacy departments
Medical colleges and rural health institutes

Plans are currently underway to implement this framework across all government medical colleges, district hospitals, and rural health institutions in the state.

A Vision for Nationwide Adoption

Experts believe that in the coming years, Waigaonkar’s Pharmacoeconomics Model should be integrated into national health procurement policies, ensuring:

Quality-driven drug selection
Reduction of hidden treatment costs
Stronger supply chain efficiency
Standardized clinical outcomes across government hospitals

As India moves toward a future of value-based healthcare, this model combines safety, science, quality, and economic efficiency—setting a new benchmark in public health management.